Literature DB >> 25895610

Mouse hospital and co-clinical trial project--from bench to bedside.

John G Clohessy1, Pier Paolo Pandolfi1.   

Abstract

Owing to the molecular complexity of cancer and the cost of therapy, researchers have begun looking to in vivo functional genomics to inform patient care. Unfortunately, xenographs of established tumour cell lines in immunodeficient mice fail to recapitulate many critical features of human primary tumours. By contrast, mouse models of cancer often faithfully recapitulate basic biology, tumour-microenvironment interactions, drug responses and therapy resistance similar to human disease. Thus, we established the co-clinical trial project, and in doing so developed the concept of the mouse hospital, whereby in vivo preclinical and early clinical studies are closely aligned, enabling in vivo testing of drugs in a multitude of cancer subtypes using mouse models, while minimizing the cost and time required to study responses in thousands of human patients. This approach can inform enrollment of patients in clinical trials, and can enable repositioning and/or repurposing of previously approved drugs.

Entities:  

Mesh:

Year:  2015        PMID: 25895610     DOI: 10.1038/nrclinonc.2015.62

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  44 in total

1.  Development of a human adaptive immune system in cord blood cell-transplanted mice.

Authors:  Elisabetta Traggiai; Laurie Chicha; Luca Mazzucchelli; Lucio Bronz; Jean-Claude Piffaretti; Antonio Lanzavecchia; Markus G Manz
Journal:  Science       Date:  2004-04-02       Impact factor: 47.728

Review 2.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

3.  Infrastructure needs for translational integration of mouse and human trials.

Authors:  John G Clohessy; Elisa de Stanchina
Journal:  Cold Spring Harb Protoc       Date:  2013-12-01

4.  Translational medicine: Cancer lessons from mice to humans.

Authors:  David Tuveson; Douglas Hanahan
Journal:  Nature       Date:  2011-03-17       Impact factor: 49.962

Review 5.  The NCI60 human tumour cell line anticancer drug screen.

Authors:  Robert H Shoemaker
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

Review 6.  Lessons from the cancer genome.

Authors:  Levi A Garraway; Eric S Lander
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

7.  Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas.

Authors:  Ping Mu; Yoon-Chi Han; Doron Betel; Evelyn Yao; Massimo Squatrito; Paul Ogrodowski; Elisa de Stanchina; Aleco D'Andrea; Chris Sander; Andrea Ventura
Journal:  Genes Dev       Date:  2009-12-15       Impact factor: 11.361

Review 8.  Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.

Authors:  L R Kelland
Journal:  Eur J Cancer       Date:  2004-04       Impact factor: 9.162

9.  Of model pets and cancer models: an introduction to mouse models of cancer.

Authors:  Andrea Lunardi; Caterina Nardella; John G Clohessy; Pier Paolo Pandolfi
Journal:  Cold Spring Harb Protoc       Date:  2014-01-01

10.  Pten dose dictates cancer progression in the prostate.

Authors:  Lloyd C Trotman; Masaru Niki; Zohar A Dotan; Jason A Koutcher; Antonio Di Cristofano; Andrew Xiao; Alan S Khoo; Pradip Roy-Burman; Norman M Greenberg; Terry Van Dyke; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  PLoS Biol       Date:  2003-10-27       Impact factor: 8.029

View more
  53 in total

Review 1.  Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets.

Authors:  Matthias Drosten; Carmen Guerra; Mariano Barbacid
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

Review 2.  Closing the 'phenotype gap' in precision medicine: improving what we measure to understand complex disease mechanisms.

Authors:  Calum A MacRae
Journal:  Mamm Genome       Date:  2019-08-19       Impact factor: 2.957

Review 3.  Prostate Cancer Research at the Crossroads.

Authors:  Michael M Shen; Mark A Rubin
Journal:  Cold Spring Harb Perspect Med       Date:  2019-07-01       Impact factor: 6.915

Review 4.  Meganucleases Revolutionize the Production of Genetically Engineered Pigs for the Study of Human Diseases.

Authors:  Bethany K Redel; Randall S Prather
Journal:  Toxicol Pathol       Date:  2015-10-28       Impact factor: 1.902

5.  Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models.

Authors:  Sai Kiran Sharma; Andrew Chow; Sebastien Monette; Delphine Vivier; Jacob Pourat; Kimberly J Edwards; Thomas R Dilling; Dalya Abdel-Atti; Brian M Zeglis; John T Poirier; Jason S Lewis
Journal:  Cancer Res       Date:  2018-01-23       Impact factor: 12.701

6.  Fishing for answers in precision cancer medicine.

Authors:  Maurizio Fazio; Leonard I Zon
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-15       Impact factor: 11.205

Review 7.  Clinical management of breast cancer heterogeneity.

Authors:  Dimitrios Zardavas; Alexandre Irrthum; Charles Swanton; Martine Piccart
Journal:  Nat Rev Clin Oncol       Date:  2015-04-21       Impact factor: 66.675

8.  Registered animal studies and null data.

Authors:  Bernd Pulverer
Journal:  EMBO Rep       Date:  2019-12-23       Impact factor: 8.807

Review 9.  Zebrafish patient avatars in cancer biology and precision cancer therapy.

Authors:  Maurizio Fazio; Julien Ablain; Yan Chuan; David M Langenau; Leonard I Zon
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

Review 10.  Applications of tumor chip technology.

Authors:  Stephanie J Hachey; Christopher C W Hughes
Journal:  Lab Chip       Date:  2018-09-26       Impact factor: 6.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.